Navigation Links
Dr. Mark Nestor Presents on Pyratine-6(TM) at the South Beach Symposium
Date:2/21/2008

NAPA, Calif., Feb. 21 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced that Dr. Mark Nestor presented on Pyratine-6(TM) at the 6th Annual South Beach Symposium in Miami.

In his presentation to leading dermatologists at the Symposium, Dr. Nestor outlined the attributes of Pyratine-6(TM) for the treatment of photodamaged skin as demonstrated in clinical trial results. Pyratine-6(TM) achieved significant improvement in skin roughness, increased skin moisture content and reduced erythema (redness due to capillary congestion) in as early as two weeks. In addition, Pyratine-6(TM) was shown to reduce mottled hyperpigmentation and fine wrinkles and was well tolerated by patients, with none of the skin irritation reported for retinoids and alpha hydroxyl acids. Based on positive results demonstrated in clinical evaluations, Pyratine-6(TM) is currently in clinical trials for the treatment of acne rosacea.

Mark S. Nestor, MD, PhD is a Clinical Associate Professor of the Department of Dermatology and Cutaneous Surgery at the University of Miami Miller School of Medicine. He serves as Director of the Center for Cosmetic Enhancement and Director of the Center for Clinical and Cosmetic Studies in Aventura, Florida. In addition, Dr. Nestor is Co-Chairman of the Board of Directors of Advanced Dermatology Management, a physician practice management company, and is currently the immediate past President of the International Society for Cosmetic and Laser Surgeons. He is the President of the American Society for Photodynamic Therapy and a Past President of the Florida Society of Dermatology and Dermatologic Surgery. Dr. Nestor is recognized as a world expert in cutaneous laser surgery, photodynamic therapy as well as the use of fillers and toxins in aesthetic medicine.

Frank Massino, Chairman and Chief Executive Officer of Senetek stated, "Pyratine-6(TM) has been well received by the dermatological community, and we are pleased that the compound is soon to complete additional clinical evaluation for the treatment of acne rosacea, a chronic dermatosis afflicting more than 45 million people worldwide."

About Senetek PLC

Senetek PLC (OTC Bulletin Board: SNKTY) is a Life Sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The Company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of the best-selling anti-aging product sold in the North American physician market.

For more information, visit the company's website at http://www.senetekplc.com.

This news release contains statements that may be considered 'forward- looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2006. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Senetek PLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
2. New Enterprise Forum Celebrates 22nd Anniversary, Presents Annual Entrepreneur Awards to Randal Charlton & Others
3. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
4. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. BAI Retail Delivery Conference Softpro Presents Next Generation Signature Tablet
7. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
8. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
9. Arpida Presents Preclinical Data on AR-2474 at ICAAC
10. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
11. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... services and solutions to the healthcare market. The company's primary focus is on ... sales and marketing strategies that are necessary to help companies efficiently bring their ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
Breaking Biology Technology:
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled ... medical LCD display is the latest premium product recently added to the range of ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
Breaking Biology News(10 mins):